Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.